Straits Times Index
3,292.93 -3.96 (-0.12%) S&P 500
5,127.79 +63.59 (+1.26%) Dow
38,675.68 +449.98 (+1.18%) Nasdaq
16,156.33 +315.33 (+1.99%) Bitcoin USD
63,703.66 -268.18 (-0.42%) CMC Crypto 200
1,326.61 +49.63 (+3.89%)
CHRS May 2024 1.000 call
| Previous close | 1.0700 |
| Open | 2.3000 |
| Bid | 0.1000 |
| Ask | 1.3500 |
| Strike | 1.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.0700 - 2.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.07k |
GlobeNewswireCoherus to Report First Quarter 2024 Financial Results on May 9, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion o
- GlobeNewswire
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114
Simply Wall St.Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
